EuBiologics said it has begun the phase 1 clinical trial of its recombinant inactive shingles vaccine, EuHZV, in Korea.
The vaccine received Investigational New Drug (IND) approval from the Ministry of Food and Drug Safety in April. The first dose was administered on Monday following an initiation meeting at Eunpyeong St. Mary's Hospital in early July.
The trial targets healthy adults aged 50 to 69, with two doses administered eight weeks apart. It aims to evaluate the safety and tolerability of both low-dose (HZV-1) and high-dose (HZV-2) versions of the vaccine.
EuHZV demonstrated equal or superior efficacy compared to the control group in preclinical trials. The vaccine's composition patent was registered in Korea in April 2024, and applications are under review in the United States and Europe.
Shingles, caused by the reactivation of the varicella-zoster virus, typically occurs when the immune system weakens,
"Utilizing our proprietary immune-enhancing platform technology, we aim to develop EuHZV into a competitive product in terms of efficacy, cost, and safety, and ultimately establish it as a blockbuster vaccine," a company official said.
Related articles
- EuBiologics license out EuMCV4 meningococcal vaccine to Eyegene
- EuBiologics licenses out meningococcal meningitis vaccine to South Africa
- EuBiologics’ 2nd plant authorized by WHO to manufacture cholera vaccine
- EuBiologics begins P1 clinical trial for RSV vaccine in Korea
- EuBiologics inks deal with DEK to supply oral cholera vaccine’s raw material to Ghana
- Efficacy study of Genematrix’s new shingles vaccine candidate published in ‘VIROLOGY’
- EuBiologics ships 1st batch of improved cholera vaccine to Niger
- Eubiologics adopts flexible pricing for cholera vaccine in UNICEF deal
- GC Biopharma’s US affiliate Curevo pulls in $110 mil. to challenge GSK’s Shingles vaccine